EN

Rankings / Health Care

Zoetis ZTS

Animal health. Zoetis Inc., listed on NYSE.

Based on the FY2025 annual report (Jan 2025 – Dec 2025)

Zoetis' market cap is
about $33.46 billion.

#281 by market cap among 289 companies, based on the Nov 5, 2026 close. FY2025 revenue was $9.467B.

Share price (close)
$82.11
Close on Nov 5, 2026 · per share
P/E ratio
13.6x
Closing price ÷ latest annual EPS
Market cap
$33.46B
#281 of 289
Revenue
$9.467B
#227 of 299 · +2.3% YoY
Operating income
—
Not reported
Net income
$2.673B
#153 of 298 · +7.5% YoY
Free cash flow
$2.283B
#156 of 261 · −0.7% YoY
Total assets
$15.467B
#252 of 299 · +8.6% YoY
Dividends paid
—
Not reported
Dividend per share
$2.03
#134 of 205 · +13.0% YoY
Dividend yield
2.5%
#55 of 203
Shares outstanding
424,927,535 shares
As of Dec 31, 2025

Where the revenue went

Revenue is set at 100% and split into what went to costs, R&D, operating expenses and taxes, and what was left as profit.

  • Cost of revenue28.2%
  • R&D7.4%
  • Other expenses29.0%
  • Income taxes & other7.3%
  • Net income28.2%

Profitability and stability

Each figure comes with its rank among 300 companies. The further right the dot, the higher the rank.

Revenue growthHow much revenue grew from the previous fiscal year
+2.3%
#237 of 299
Revenue was roughly flat. The median across 299 companies is +7.9%.
Operating marginShare of revenue kept as profit from the core business
—
Not ranked
The filing doesn't include the items needed to calculate this.
Net marginShare of revenue left as profit after interest and taxes
28.2%
#48 of 298
After taxes, 28.2% of revenue was left as net income. The median across 298 companies is 14.0%.
FCF marginShare of revenue left as cash after capital spending
24.1%
#65 of 261
Plenty of cash is left after capital spending. The median across 261 companies is 15.8%.
ROEHow much profit the company earned on shareholders' equity in a year
66.0%
#30 of 276
Earns a lot relative to its equity. The median across 276 companies is 16.8%.
Debt-to-equityLiabilities relative to equity. Lower means less debt
364.3%
#205 of 244
Liabilities are more than twice equity. The median across 244 companies is 159.6%.

Revenue and profit over time

Gray bars show revenue and the green part inside shows net income. The number above each bar is revenue (abbreviated) and the number below is net margin. Hover over a bar to see the exact amounts.

FY2021 Revenue $7.776B / Net income $2.037B7.78B26.2%FY2021FY2022 Revenue $8.08B / Net income $2.114B8.08B26.2%FY2022FY2023 Revenue $8.544B / Net income $2.344B8.54B27.4%FY2023FY2024 Revenue $9.256B / Net income $2.486B9.26B26.9%FY2024FY2025 Revenue $9.467B / Net income $2.673B9.47B28.2%FY2025
Currency: US dollars. Years are the years in which each fiscal year ended.

Where the cash went

Unlike profit, cash flow is money that actually came in and went out.

  • Cash from operations$2.904B
  • Capital spending−$621M
  • Free cash flow (FCF)$2.283B

Whose money funds the assets

The company's assets, split into borrowed money (liabilities) and shareholders' money (equity).

  • Total assets$15.467B
  • Total liabilities$12.136B
  • Total equity$3.331B
  • Cash and equivalents$2.312B

Compared with similar companies

Based on each company's latest annual report, so fiscal year ends may differ.

Compare in detail
CompanyAnnual revenueNet incomeRevenue growthOperating marginNet margin
ZoetisZTS$9.467B$2.673B+2.3%—28.2%
Bristol Myers SquibbBMY$48.194B$7.054B−0.2%—14.6%
PfizerPFE$62.579B$7.771B−1.6%—12.4%
MerckMRK$65.011B$18.254B+1.3%—28.1%
AbbVieABBV$61.16B$4.226B+8.6%24.6%6.9%

What the company does

Zoetis is the world's largest animal health company, making vaccines, parasite treatments and dermatology drugs for pets and livestock.

The fiscal year ends around December each year.

Related companies: Bristol Myers Squibb, Pfizer, Merck, AbbVie

Financial statements

Last 5 fiscal years. Currency: US dollars.

Show the table
ItemFY2021FY2022FY2023FY2024FY2025
Revenue7.776B8.08B8.544B9.256B9.467B
Cost of revenue2.303B2.454B2.561B2.719B2.666B
Gross profit5.473B5.626B5.983B6.537B6.801B
R&D expense508M539M614M686M698M
Pretax income2.488B2.656B2.936B3.133B3.36B
Net income2.037B2.114B2.344B2.486B2.673B
EPS (diluted)$4.27$4.49$5.07$5.47$6.02
Operating cash flow2.213B1.912B2.353B2.953B2.904B
Capital expenditures477M586M732M655M621M
Free cash flow (FCF)1.736B1.326B1.621B2.298B2.283B
Total assets13.9B14.925B14.286B14.237B15.467B
Total liabilities9.356B10.522B9.295B9.467B12.136B
Total equity4.544B4.403B4.991B4.77B3.331B
Cash and equivalents3.485B3.581B2.041B1.987B2.312B
Original filing10-K10-K10-K10-K10-K

Source: SEC EDGAR filings for Zoetis Inc. · CIK 0001555280 · US-GAAP